Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 78Prostatic Neoplasms, Castration-Resistant 3Neoplasm Metastasis 3Prostatic Diseases 2Neoplasms 2Genital Diseases, Male 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Neoplasms, Male 1Castration Levels of Testosterone 1

Interventions

pertuzumab 1pazopanib 1enzalutamide 1decitabine and cedazuridine drug combination 1apalutamide 1Trastuzumab 1Surgical Procedures, Operative 1Sunitinib 1Risk Assessment 1Radiotherapy 1Preoperative Exercise 1Opdualag 1Nutritional Support 1Nivolumab 1Injections, Subcutaneous 1Exercise 1Ethanol 1Bandages, Hydrocolloid 1Ado-Trastuzumab Emtansine 1Adiposity 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Patient Preference × apalutamide × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡